Status:
COMPLETED
Social-software iMproving wARfarin Therapy
Lead Sponsor:
Wuhan Asia Heart Hospital
Conditions:
Anticoagulants Causing Adverse Effects in Therapeutic Use
Patient Compliance
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Poor anticoagulation quality is a major problem among Chinese patients receiving warfarin therapy in traditional health care settings. Improving warfarin therapy has been crucial for Chinese patients....
Detailed Description
Social software is becoming a necessary of life. Wechat, powered by Tencent company, is the most popular social software in China. People can chat with others no matter how far away from each other. ...
Eligibility Criteria
Inclusion
- Received mechanical valve replacement;
- Receiving warfarin anticoagulation therapy;
- Have smartphone and Know how to use wechat application and our mini-program;
- be expected to survive for the duration of the study;
- not be suffering from intracranial bleeding (intracranial haemorrhage, subarachnoid haemorrhage, hemorrhagic stroke) or any other contraindication described in the warfarin package insert;
- be willing to be randomized;
- sign the informed consent form;
- not be enrolled in another randomized clinical trial that involves a drug or device intervention.
Exclusion
- subject has had an intracranial haemorrhage, subarachnoid haemorrhage, hemorrhagic stroke, or any other absolute/major contraindication described in the warfarin package insert within the last month
- subject enrolled in another randomized clinical trial that involves a drug or device intervention
- subject is not able to follow the protocol and all related instructions and does not have a caregiver with these skills
- Patients were considered being not suitable for this study
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2019
Estimated Enrollment :
735 Patients enrolled
Trial Details
Trial ID
NCT03264937
Start Date
September 1 2017
End Date
March 8 2019
Last Update
June 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WAHH
Wuhan, Hubei, China, 430000